Evidence map›Paper›PMID 38664244›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2024

Asiaticoside alleviates lipopolysaccharide-induced acute lung injury by blocking Sema4D/CD72 and inhibiting mitochondrial dysfunction in RAW264.7 cell and mice.

Jianhua Zhang, Hao Zhao, Fang Wang, Jie Zhou, Mao Li, Hua Li, Meiping Ren, Lulu Wang, Qingyi Ren, Xiaolin Zhong and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Therapeutic potential ofPharmaceutical biology · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Jianhua Zhang *Department of Anesthesiology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Hao Zhao *Department of Pharmacy, The Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University, Luzhou, China.
Fang WangSchool of Pharmacy, Southwest Medical University, Luzhou, China.
Jie ZhouSchool of Pharmacy, Southwest Medical University, Luzhou, China.
Mao LiDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China.
Hua LiDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China.
Meiping RenDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China.
Lulu WangDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China.
Qingyi RenSchool of Pharmacy, Southwest Medical University, Luzhou, China.
Xiaolin ZhongDepartment of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Xian JiangDepartment of Anesthesiology, Luzhou People's Hospital, Luzhou, China. 441315510@qq.com.
Zhuo ZhangDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China. zhuozhang@swmu.edu.cn.
Southwest Medical University · CNAffiliated Hospital of Southwest Medical University · CNQingzhou City People's Hospital · CN

Funding

Luzhou Science and Technology Bureau 2021JYJ-82Sichuan Province Science and Technology Support Program 2022YFS0633The second batch of planned projects of Science and Technology Department of Sichuan Provincial 2022NSFSC0816
6 · The paper itself

Abstract

Acute lung injury (ALI) is a common disease with complex pathogenesis. However, the treatment is mainly symptomatic with limited clinical options. Asiaticoside (AS), a Chinese herbal extract, has protective effects against LPS-induced ALI in mice and inhibits nitric oxide and prostaglandin E2 synthesis; however, the specific mechanism of AS in the prevention and treatment of LPS-induced ALI needs further study. Sema4D/CD72 pathway, mitochondrial dysfunction, and miRNA-21 are closely associated with inflammation. Therefore, the present study aimed to explore whether AS exerts its therapeutic effect on ALI by influencing Sema4D/CD72 pathway and mitochondrial dysfunction, restoring the balance of inflammatory factors, and influencing miRNA-21 expression. Cell and animal experiments were performed to investigate the effect of AS on ALI. Lipopolysaccharide (LPS) was used to establish the ALI model. CCK8 and flow cytometry were used to detect the cell viability and apoptosis rate. HE staining and wet-to-dry weight ratio (W/D) of lung tissue were determined. The expressions of Sema4D, CD72, NF-κB p65, Bax, Bcl2, and caspase 3 in RAW264.7 cells and lung tissues were detected by western blot, and the levels of IL-10 and IL-1β induced by LPS in supernatant of RAW264.7 cells and BALF were measured by ELISA. And the expression of miRNA-21 in cells and lung tissues was detected by fluorescence quantitative PCR. The result shows that AS treatment suppressed LPS-induced cell damage and lung injury in mice. AS treatment could alleviate the pathological changes such as inflammatory infiltration and histopathological changes in the lungs caused by LPS, and reduce the ratio of W/D. AS significantly alleviated the decrease of mitochondrial membrane potential induced by LPS, inhibited the increase of ROS production, and reduced the expression of mitochondrial fission proteins Drp1 and Fis1. The high-dose AS group significantly downregulated the expression of Sema4D, CD72, phosphorylated NF-κB p65, and apoptosis-related proteins, decreased the pro-inflammatory factor IL-1β, and enhanced the level of anti-inflammatory factor IL-10. In addition, AS promoted miRNA-21 expression. These effects inhibited apoptosis and restored the balance between anti- and pro-inflammatory factors. This represents the inaugural report elucidating the mechanism by which AS inhibits the Sema4D/CD72 signaling pathway. These findings offer novel insights into the potential application of AS in both preventing and treating ALI.

Indexed as

Acute Lung InjuryLipopolysaccharidesMitochondriaSemaphorinsTriterpenesAnimalsAnti-Inflammatory AgentsApoptosisLungMaleMiceMice, Inbred C57BLMicroRNAsRAW 264.7 CellsSignal TransductionAnti-Inflammatory AgentsasiaticosideLipopolysaccharidesMicroRNAsMIRN21 microRNA, mouseSemaphorinsTriterpenesAsiaticosideLipopolysaccharide-induced acute lung injuryMicroRNA-21Mitochondrial dysfunctionSema4D

Identifiers

PMID38664244
PMCPMC11450039
OpenAlexW4395677524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.